Core Insights - Abbott Laboratories (ABT) has received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR) system, which addresses severe mitral annular calcification (MAC) and enhances the company's Structural Heart portfolio [1][8] - The TMVR market is expected to grow at a compound annual growth rate (CAGR) of 20% from 2025 to 2030, driven by the increasing prevalence of mitral valve diseases, preference for minimally invasive procedures, and an expanding geriatric population [2] - The Tendyne system provides a minimally invasive alternative for high-risk patients who cannot undergo open-heart surgery, with a unique design that allows for adaptability to various patient anatomies [3][4][8] Competitive Landscape - Edwards Lifesciences (EW) is actively developing transcatheter heart valve technologies, including the PASCAL Precision system for mitral and tricuspid regurgitation and the EVOQUE system for tricuspid valve replacement [5] - Medtronic (MDT) offers a range of therapies for heart valve disorders, including the CoreValve family and various surgical solutions, positioning itself as a key player in the structural heart market [6] Financial Performance - Abbott's stock has increased by 19.2% over the past year, outperforming the industry growth of 6.2% and the S&P 500's growth of 17.8% [7] - The current forward Price-to-Sales (P/S) ratio for Abbott is 4.87X, which is lower than the industry average of 5.56X, indicating a potentially discounted valuation [9]